

## Press Release

# Daiichi Sankyo Announces Global Management Structure and Corporate Officers

**Tokyo, Japan - (February 21, 2022)** – Daiichi Sankyo Company, Limited today announced its Global Management Structure and appointment of Corporate Officers effective from April 1, 2022.

### 1. Global Management Structure

Name	Current Responsibilities*	New Responsibilities
Sunao Manabe	Chief Executive Officer	Unchanged

#### Corporate Units

Name	Current Responsibilities*	New Responsibilities
Takashi Fukuoka	—	Head of Corporate Strategy Unit (Global Head of Corporate Strategy)
Hiroyuki Okuzawa	Head of Corporate Planning & Management Unit, CFO (Global Head of Corporate Planning & Management)	Unchanged
Masahiko Ohtsuki	Head of Digital Transformation Management Unit, CIO (Global Head of Digital Transformation Management)	Unchanged
Stuart Mackey	Head of Business Development Unit (Global Head of Business Development)	Unchanged
Hironobu Furuta	Head of Corporate Affairs Unit, CISO (Global Head of Corporate Affairs)	Unchanged

#### Business Units

Name	Current Responsibilities*	New Responsibilities
Shoji Hirashima	Head of Corporate Strategy Unit (Global Head of Corporate Strategy)	Head of Japan Business Unit
Ken Keller	Head of Oncology Business Unit (Global Head of Oncology Business)	Unchanged
Jan Van Ruymbeke	Head of EU Specialty Business Unit	Unchanged
Kiminori Nagao	Head of ASCA Business Unit	Unchanged

Name	Current Responsibilities*	New Responsibilities
Paul Diolosa	Head of American Regent Unit	Unchanged
Katsuhiko Yoshida	Head of Daiichi Sankyo Healthcare Unit	Unchanged

#### Functional Units

Name	Current Responsibilities*	New Responsibilities
Ken Takeshita	Head of Research & Development Unit (Global Head of Research & Development)	Unchanged
Masayuki Yabuta	Head of Biologics Unit (Global Head of Biologics)	Unchanged
Toshi Kajiro	—	Head of Pharmaceutical Technology Unit (Global Head of Pharmaceutical Technology)
Hiroto Kashiwase	Head of Pharmaceutical Technology Unit (Global Head of Pharmaceutical Technology)	Head of Supply Chain Unit (Global Head of Supply Chain)
Toshinobu Taki	—	Head of Quality Assurance & Regulatory Affairs Unit (Global Head of Quality Assurance & Regulatory Affairs)
Kento Wada	Head of Clinical Safety & Pharmacovigilance Unit (Global Head of Clinical Safety & Pharmacovigilance)	Unchanged

#### General Counsel

Name	Current Responsibilities*	New Responsibilities
Naoto Tsukaguchi	General Counsel	Unchanged

\* Responsibilities under current Global Management Structure

## 2. Corporate Officers (Daiichi Sankyo Company, Limited)

Name	Current Responsibilities	New Responsibilities
Sunao Manabe	Representative Director President & CEO	Unchanged
Satoru Kimura	Representative Director Senior Executive Officer Head of Japan Business Unit	Representative Director
Masahiko Ohtsuki*	Director Senior Executive Officer Head of Digital Transformation Management Div. CIO	Unchanged
Shoji Hirashima*	Director Senior Executive Officer Head of Corporate Strategy Div.	Director Senior Executive Officer Head of Japan Business Unit
Hiroyuki Okuzawa*	Director Executive Officer Head of Corporate Planning & Management Div. CFO	Director Senior Executive Officer Head of Corporate Planning & Management Div. CFO
Hironobu Furuta*	Executive Officer Head of Corporate Affairs Div. CISO	Unchanged
Masayuki Yabuta*	Executive Officer Head of Biologics Div.	Unchanged
Wataru Takasaki	Executive Officer Head of R&D Div.	Executive Officer Head of R&D Div. & Vice President of Precision Medicine Function
Takashi Fukuoka*	Corporate Officer Executive Vice President, R&D Affairs, Daiichi Sankyo, Inc.	Executive Officer Head of Corporate Strategy Div.
Hiroto Kashiwase*	Corporate Officer Head of Pharmaceutical Technology Div.	Executive Officer Head of Supply Chain Div.
Koji Ogawa	Corporate Officer Head of US Corporate Div., Daiichi Sankyo, Inc.	Unchanged
Tomoji Hashiba	Corporate Officer In charge of External Affairs	Unchanged
Miyuki Arai	Corporate Officer Head of Quality Assurance & Regulatory Affairs Div.	Corporate Officer In charge of QARA & CSPV**
Toru Takahashi	Corporate Officer Vice President of Research Function, R&D Div.	Unchanged
Naoto Tsukaguchi	Corporate Officer Vice President of Legal Affairs Dept., Corporate Affairs Div.	Unchanged

Name	Current Responsibilities	New Responsibilities
Akio Sakurai	Corporate Officer Head of Sales Div., Japan Business Unit	Unchanged
Toshinori Agatsuma	Corporate Officer Vice President of Oncology Research Laboratories I, Research Function, R&D Div.	Unchanged
Yoshinori Kaneshima	Corporate Officer Head of Marketing Div., Japan Business Unit	Unchanged
Kiminori Nagao*	Corporate Officer President of ASCA Company	Corporate Officer Head of ASCA Business Div.
Nobuo Murakami	Corporate Officer Vice President of Corporate Strategy Dept., Corporate Strategy Div.	Unchanged
Takashi Matsumoto	Corporate Officer In charge of Human Resources	Corporate Officer Global Head of HR
Hiroshi Masumoto	Vice President of Data Intelligence Dept., Digital Transformation Management Div.	Corporate Officer Vice President of Data Intelligence Dept. & Senior Director of Data Governance & Data Engineering Group, Digital Transformation Management Div.
Shizuko Ueno	Vice President of Clinical Development Dept. III, Development Function, R&D Div.	Corporate Officer Head of Medical Affairs Div., Japan Business Unit
Akihiro Inoguchi	Vice President of Development Function, R&D Div.	Corporate Officer Vice President of Development Function, R&D Div.
Toshi Kajiro*	Vice President of Analytical & Quality Evaluation Research Laboratories, Pharmaceutical Technology Div.	Corporate Officer Head of Pharmaceutical Technology Div.
Hiroya Senda	Vice President of Sales Planning Dept., Sales Div., Japan Business Unit	Corporate Officer Vice President of Sales Planning Dept., Sales Div., Japan Business Unit
Satoru Ogawa	Vice President of Secretariat Dept.	Corporate Officer Vice President of Secretariat Dept.
Atsushi Tsukamoto	Vice President of Development Regulatory Affairs Dept., Development Function, R&D Div.	Corporate Officer Head of Therapeutic Area Strategies, Daiichi Sankyo, Inc.

\*Unit Head in Global Management Structure as of April 1, 2022

\*\* QARA: Quality Assurance & Regulatory Affairs, CSPV: Clinical Safety & Pharmacovigilance

◇ Kentaro Takamura and Junichi Fukute (current Executive Officer), and Hideyuki Hirano (current Corporate Officer) will be appointed Corporate Adviser as of April 1, 2022.

◇ Seiichiro Kumakura and Hironobu Saito (current Corporate Officer) will be appointed Senior Adviser as of April 1, 2022.

## **About Daiichi Sankyo**

Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical need. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.” For more information, please visit [www.daiichisankyo.com](http://www.daiichisankyo.com).

### **Media Contacts:**

#### **Japan:**

Masashi Kawase  
Daiichi Sankyo Co., Ltd.  
[kawase.masashi.a2@daiichisankyo.co.jp](mailto:kawase.masashi.a2@daiichisankyo.co.jp)  
+81 3 6225 1126 (office)

#### **Investor Relations Contact:**

[DaiichiSankyoIR@daiichisankyo.co.jp](mailto:DaiichiSankyoIR@daiichisankyo.co.jp)